There has been an advance in our understanding of the mechanisms of diabetic nephropathy over the past few years and much of that has occurred because of studies in animal models of diabetic nephropathy.
INTRODUCTION
Diabetes mellitus is the major cause of end-stage renal disease (ESRD) in the United States and elsewhere, and its incidence has increased by more than 50% in the last 10 years [1] . Despite this trend, only a minority of individuals with either type 1 or type 2 diabetes develop nephropathy, indicating that specific environmental or genetic factors must contribute to its initiation and progression. Although clear progress has been made in understanding the disease process, there has been limited success in identifying specific factors that cause human nephropathy and its progression. One of the reasons for the slow evolution in our understanding of diabetic nephropathy is the lack of reliable animal models that mimic human disease. Over the past 15 years, there has been a concerted effort by many individual investigators and consortia to address this deficiency [2, 3] . Although this effort has produced a number of important advances, there have been no new models of any diabetic complication that fully reproduce the human phenotype. This lack of a 'perfect model' has led to a growing consensus that animal models are best used to provide clues about the pathogenesis of the human disease, but at present cannot serve as miniature replicas to plot the course of human complications. In addition, it appears that most animal models described to date represent, at best, early changes of diabetic kidney disease [3,4 & ]. Thus, most of the information derived from the analysis of these models likely provides only limited or indirect information about the factors critical for progressive kidney disease in patients with diabetic kidney disease. That being said, many new pathways and potential targets for intervention have been suggested from animal models over the past several years. The purpose of this review will be to underline some of the more interesting new pathways and targets, and to evaluate the evidence supporting their potential role in diabetic kidney disease in humans. We will concentrate on the data from mouse models, as these have been the workhorses of diabetic complications research over the past few years.
CURRENT STATE OF MOUSE MODEL RESEARCH IN DIABETIC KIDNEY DISEASE
Although no reported animal models fully replicate the human condition of progressive diabetic nephropathy, some models are better than others. One clear-cut finding over the past 10 years has been the important effect of genetic background on the development and severity of diabetic changes in the kidney of mouse models. Indeed, the mouse strain most commonly used for many experimental studies, the C57BL/6 strain, is remarkably resistant to diabetic injury [2, 3] . Thus, most experts in the field have concluded that pathways identified in this model are suspect unless validated in another model (e.g., mouse strain with a more susceptible background) or in humans [3, 5] . This is especially true for experiments that purport to mitigate disease. In the discussion below, therefore, we will emphasize the strain of mice that have been studied to aid in the interpretation of results.
CHANGES IN PATHWAYS THAT PROMOTE DIABETIC KIDNEY DISEASE IN MICE
The bulk of this review will focus on the reports that have been published or presented in the last 2 years and have either identified new potential targets and pathways or altered our thinking about older ones. Thus, it is not a survey of important factors in the pathogenesis of diabetic nephropathy. Although we organize this section based on the pathway or target being addressed by specific studies, we believe that the pathogenesis of diabetic nephropathy is complex and multidimensional involving the interaction of many pathways and networks of abnormalities. With the advent of genomewide analytical capabilities, it is now feasible to simultaneously analyze multiple regulatory biological systems at high precision and depth. We emphasize the utility of this strategy, especially in moving from animal model research to human studies. To help facilitate this analysis, we have utilized the online database, Nephromine (www.nephromine.org), which provides curated data from all published (and some unpublished) genomewide expression studies in humans with any type of kidney disease, including diabetic nephropathy. Nephromine provides sophisticated analytical tools that we have utilized in the simplest way to interrogate the expression levels in human diabetic nephropathy of the target genes described in the mouse models reported below. The human diabetic nephropathy database used for this analysis is from a recently published Affymetrix expression array study [6] used to identify differentially regulated transcripts in microdissected human kidney samples, 22 of which were from patients with diabetes. Diabetic nephropathy samples were significant for their racial diversity and decreased glomerular filtration rate (25-35 ml/ min). Stringent statistical analysis was used to identify differentially expressed transcripts in control and diseased glomeruli and tubuli.
Reduction in endothelial nitric oxide synthase (NOS3) activity predisposes to diabetic nephropathy
It has become increasingly clear that one of the best mouse models of diabetic nephropathy is the endothelial nitric oxide synthase (eNOS) knockout mouse. This appears to be true irrespective of the genetic background of the mice or the cause of
KEY POINTS
Animal models, including mouse models, represent early changes, and can be best used to provide clues about the pathogenesis of diabetic nephropathy, but will not serve as miniature replicas of humans with the disease.
Changes in animal models need to be validated in human diabetic nephropathy before assuming that they are involved in the actual pathogenesis of the disease.
Alterations in multiple pathways are required to produce the changes found in human diabetic nephropathy and systems biological methods can provide a window into this complexity.
A number of new pathways potentially involved in human diabetic nephropathy have been recently described or more clearly elucidated in mouse model studies, including alterations involving dopamine, eNOS, JAK1/2, mTORC-1, and Nrf-2.
experimental diabetes [3, [7] [8] [9] . This has brought the role of eNOS in preventing disease as well as endothelial defects in diabetic nephropathy to the fore. A recent study [10 & ] explored the effect of experimental diabetes on eNOS activity in cultured endothelial cells and in a type 2 model of diabetes (C57BLKS db/db mouse). High glucose increased endothelial permeability in cultured cells, and reduced eNOS dimer formation and phosphorylation both in the cultured cells and in glomeruli from diabetic mice. These abnormalities were reversed by supplementation with precursors of either the eNOS cofactor, tetrahydrobiopterin, or of nitric oxide itself. Importantly, these interventions also reduced some of the diabetic nephropathy pathology and other findings in the mouse model, including reduced basement membrane thickening and albuminuria and reduced evidence of oxidative stress [10 & ]. There were no changes in eNOS mRNA or monomer protein expression, as the defects were posttranslational, but this study is important for showing that hyperglycemia and diabetes can reduce eNOS function. It seems reasonable that similar effects could be found in humans with diabetic nephropathy as the murine model that lacks eNOS function replicates important features of advanced human diabetic nephropathy and has been shown to have a better overlap in glomerular gene expression with that in human diabetic nephropathy than the two other murine diabetic nephropathy models that were studied [4 & ]. Finally, in a rat model of diabetic kidney disease and hypertension, eNOS uncoupling has been corroborated as a major factor in disease progression and in accumulation of reactive oxygen species (ROS) in kidney cortex. Interestingly, these abnormalities were largely reversed by green tea
To analyze the role of eNOS gene expression in diabetic nephropathy in humans, we explored the changes in diabetic nephropathy collated in Nephromine. As expected, there was not a significant change in eNOS mRNA levels in either glomeruli or tubulointerstitial regions from humans with progressive diabetic nephropathy (data not shown). The data support scenarios by which a change in activity of eNOS, rather than a change in eNOS expression, is an important mediator of human and rodent diabetic nephropathy.
Accordingly, a reduction in eNOS activity remains an attractive, but unproven, cause of diabetic nephropathy in humans and a potential target for intervention. As an additional indicator of plausibility, Smithies' group has found increased nephropathy in mice with changes in eNOS (NOS3) expression that are similar to those associated with the variants found in humans [12 & ]. Thus, normal variations in eNOS expression might alter the risk of progressive diabetic nephropathy in humans, although statistically lower eNOS expression in kidney tissues was not identified in the Nephromine analysis.
Reduction in leptin and leptin receptor signaling may predispose to diabetic complications
A leading model of type 2 diabetes and diabetic nephropathy, the db/db mouse, is both strain dependent and dependent on leptin deficiency due to a mutation in the leptin receptor. A recently described model of morphologically advanced diabetic nephropathy is dependent on leptin deficiency via the ob/ob mutation of leptin and is also strain dependent, as the robust nephropathy develops in BTBR mice but not in other strains with the same mutation (e.g., C57BL/6). There is evidence that the susceptibility of this strain to develop diabetic complications results from a unique interaction between genomic features of the BTBR strain and disrupted leptin signaling. For example, BTBR wildtype mice with intact leptin signaling made diabetic by the administration of streptozotocin (STZ) do not develop complications comparable to BTBR ob/ob mice. Also, BTBR ob/ob mice, treated with a PPAR-a agonist to lower blood glucose, do not show improvement in diabetic nephropathy and leptin replacement reverses diabetic nephropathy in this strain [13, 14] . These studies have not clarified whether the salutary effects of leptin replacement are the result of leptin activity in the central nervous system or the result of signaling in the kidney. A PET imaging study has shown leptin uptake in renal tubules via the megalin receptor, but did not report uptake within glomeruli (even though megalin is present in rodent glomeruli). There are few data at present that clarify how leptin acts on kidney cells, and so the basis for the contribution of leptin deficiency to the development of diabetic nephropathy in BTBR mice remains obscure.
In our Nephromine analysis of changes in leptin and the leptin receptor in human diabetic nephropathy, there was no change in leptin levels, but there was a significant 1.7-fold increase in leptin receptor expression in the tubulointerstitium of patients with progressive diabetic nephropathy compared to controls.
The Nephromine findings fit well with the PET imaging studies in suggesting the activity of leptin in the tubulointerstitium, whether via megalin or other receptors in mice or by distinct leptin receptors in humans. Both the Nephromine and PET structures pose an as yet unexplained discrepancy between the striking glomerular changes and the very modest tubulointerstitial changes that develop in leptin-deficient BTBR mice.
The role of NADPH oxidase in reactive oxygen species mediated pathology in diabetic nephropathy
Given the clear role of ROS in the pathogenesis of diabetic nephropathy, much effort has focused on identifying the sources of enhanced oxidative stress in kidney cells and determining which are most important in disease progression. Given the complexity of the disease process, it is not surprising that multiple sources including mitochondrial, cytoplasmic, and membrane-associated mediators of ROS accumulation have been identified and shown to play potential roles in experimental diabetic nephropathy. One area of relatively recent focus is the potential role of NADPH oxidases in diabetic nephropathy progression. Recent and promising observations about the role of these enzymes have come from the studies that modulate expression or activity of the NADPH oxidase catalytic subunit, NOX4, that is expressed in the kidney at high levels.
These studies have shown that NOX4 levels and activity are increased in rat and mouse models of diabetic nephropathy [15] [16] [17] including in the robust OVE26 FVB mouse model [15] , and that inhibition of NOX4 reduces glomerular changes of diabetic nephropathy in mice. A recent study found that a novel NOX1/4 inhibitor also reversed early diabetic nephropathy changes in BLKS db/db mice, but that the effects were not sustained. Worrisomely, in this study, albuminuria ultimately increased to a higher level than that seen in untreated diabetic animals [18] .
Confounding the findings in rodent models is the observation that NOX4 levels were not changed in glomeruli or tubulointerstitium of humans with diabetic nephropathy in our Nephromine analysis, although NOX2 levels were significantly increased around two-fold in both compartments. There is a relative paucity of experimental data in experimental diabetic nephropathy that would explain the basis for the elevated NOX2 identified in humans.
ROS generated by NADPH oxidases clearly accentuated progressive diabetic nephropathy by stimulating tissue damage, inflammation, and fibrosis. Given its high expression in kidney cells, NOX4 studies have predominated, but as NOX2 is also expressed in kidney [19] and vascular cells [20] , and its expression appears to be altered in human diabetic nephropathy, studies of the role of NOX2 in the pathogenesis of diabetic nephropathy are in order.
Activation of NFE2-related factor 2 and downstream effectors reduces diabetic nephropathy
Another important regulator of oxidative stress in cells is NFE2-related factor 2 (Nrf2). This molecule regulates the expression of numerous genes including antioxidant enzymes, such as NADPH quinine oxidoreductase 1, glutathione S-transferase, heme oxygenase-1 (HO-1), glutathione peroxidase, glutamate cysteine ligase, and peroxiredoxin I, which can counteract both proinflammatory signals as well as oxidative stress [21] . Thus, Nrf2 and its negative regulator, Keap1, are attractive targets to modulate in diabetic nephropathy. A recent report of a phase 2 clinical trial with an agent that activates Nrf2, bardoxolone methyl, has prompted even greater attention to this pathway as potentially protective in diabetic nephropathy [22] . The animal data supporting the role of Nrf2 in counteracting diabetic kidney damage include a study showing that Nrf2 knockout mice on a C57Bl/6 background developed greater nephropathy (expanded mesangium) after being made diabetic with low-dose STZ injections than did wildtype diabetic mice. Albuminuria increased approximately three-fold in the knockout diabetic animals compared to a roughly two-fold increase in the wildtype diabetic animals, compared to their respective nondiabetic counterparts [23] . As in other studies on C57BL/6 animals, the degree of nephropathy, even in the Nrf2 knockout animals, was modest. A more recent study from the same group showed that Nrf2 activation by exogenous dietary compounds, such as sulforaphane and cinnamic aldehyde, can reduce diabetic nephropathy in the same models and is effective in both Nrf2 knockout and wildtype animals, suggesting that at least some of the helpful effects of the dietary compounds were independent of Nrf2, although the compounds also had a major glucose-lowering effect which could have accounted for much of this protection [24 & ]. In the same study, humans with diabetic nephropathy were found to have high endogenous glomerular Nrf2 activity, which raises the question of whether activating Nrf2 more completely or earlier will substantially ameliorate diabetic nephropathy progression.
In our Nephromine analysis, Nrf2 gene expression was not altered, but several of its downstream targets such as peroxiredoxin I, glutathione peroxidase 1, and HO-1 showed increases in expression (or trends in that direction) in both glomerular and tubulointerstitial compartments in progressive human diabetic nephropathy (Fig. 1) . HO-1 itself is a potential target for the modulation of diabetic nephropathy [25] . As is the case for Nrf2, induction of HO-1 activity can prevent at least some aspects of diabetic nephropathy in rodent models [26] .
These studies suggest that humans with diabetic nephropathy already have substantial upregulation of antioxidant responses by the time nephropathy is evident, and underline the question of whether superinduction of antioxidant regulators or enzymes will further ameliorate the disease process.
Podocyte mammalian target of rapamycin complex 1 activity contributes to diabetic nephropathy
While a number of studies have suggested that enhanced mammalian target of rapamycin (mTOR) activity contributes to glomerular hypertrophy and proteinuria, the most compelling data supporting the role of mTOR in diabetic nephropathy have come from two recent studies [27 && ,28 && ]. These studies used parallel but complementary methods to assess the role of podocyte mTOR complex (mTORC) in diabetic nephropathy. Critically, they separated out the effects of the two different mTOR complexes, mTORC1 and mTORC2 [28 && ]. Activation of mTORC1 specifically in podocytes by genetic deletion of an upstream negative regulator led to many changes of diabetic nephropathy including albuminuria, glomerular basement membrane widening, podocyte loss, mesangial expansion, and glomerular mesangial accumulation of fibronectin and collagen IV. All of these alterations were at least partly prevented by treatment with the mTORC1 inhibitor rapamycin, which also produced similar changes in the db/db model of diabetic nephropathy [27 && ]. These changes were prevented by a podocyte-specific genetic reduction in mTORC1 expression reduction via heterozygous deletion of raptor, a specific component of mTORC1. Although these studies indicate that targeting mTORC1 for therapy of diabetic nephropathy is attractive, the difficulty of such a strategy was underlined by the finding that elimination of raptor expression in podocytes resulted in significant proteinuria [28 && ]. Nephromine analysis did not show a significant increase in mTOR expression in either glomeruli or tubulointerstitium in progressive human diabetic nephropathy, but did suggest that downstream targets, based on the canonical signaling pathway found in Biocarta Pathways (www.biocarta.com), might be generally increased in expression in the tubulointerstitium (not shown). This finding would require further analysis to confirm.
An increase in mTORC1 activity in podocytes likely plays a significant role in the glomerular changes of diabetic nephropathy. However, reduced mTOR activity and mTOR inhibitors in humans can also lead to glomerular pathology and proteinuria [27 && ,28 && ,29] . Added to this complexity is the incompletely understood interaction of mTORC1 and mTORC2 and the apparent age and condition-specific responses to manipulation of mTORC1, which make it a less attractive target in diabetic nephropathy until more is learned about the potential benefits and risks of long-term mTORC1 inhibition.
Enhanced Janus kinase/signal transducer and activator of transcription expression and signaling appears to contribute to progressive diabetic nephropathy
Over the past few years, the role of the Janus kinase/ signal transducer and activator of transcription (JAK/STAT) pathway in diabetic nephropathy, and other chronic kidney diseases, has garnered attention. These studies began with Marrero's work a decade ago showing that JAK2 activation resulted in diabetic glomerulopathy [30] and were expanded by human data showing substantial upregulation of multiple genes in this system that, in the tubulointerstitium, tightly correlated with a decline in glomerular filtration rate [31] . In addition, increased expression of endogenous STAT inhibitors, the suppressors of cytokine signaling proteins SOCS-1 and SOCS-3, inhibited early changes of diabetic nephropathy in a STZ-diabetic rat model [32] . We have performed a cross-species comparison of glomerular transcriptional networks in diabetic nephropathy. Glomerular gene expression was profiled in patients with early type 2 diabetic nephropathy as well as in three of the better current mouse diabetic nephropathy models (STZ-diabetic DBA/2 mice, C57BLKS db/db mice, and eNOS-deficient C57BLKS db/db mice). Species-specific transcriptional networks were generated and compared using a novel network-matching algorithm. Shared genes across all networks reflected the important role of JAK-STAT signaling pathways, as the largest number of conserved changes were in these pathways [4 & ]. Nephromine analysis showed that JAK1 (Fig. 2) , JAK2, STAT1, and STAT3, but not STAT5a or 5b, SOCS-1, or SOCS-3 were significantly increased in the tubulointerstitium in human progressive diabetic nephropathy.
The activation of JAK/STAT signaling appears to trigger both inflammatory and profibrotic responses, and may modulate angiotensin II signaling in the kidney. In addition, in recent unpublished data, we have found that specific overexpression of JAK2 in podocytes augments mesangial expansion and albuminuria in a mouse diabetic model (H. Zhang, F. C. Brosius, unpublished observation). A phase 2 clinical trial of a JAK1/JAK2 inhibitor (ClinicalTrials.gov identifier: NCT01683409) will help determine whether this pathway is a viable one for targeting in progressive diabetic nephropathy.
Bone morphogenic proteins modulate diabetic nephropathy
Reams of evidence point to transforming growth factor (TGF)-b activation as a critical inducer of the glomerular and tubulointerstitial fibrosis that is a hallmark of progressive diabetic nephropathy. A major downstream target of TGF-b is connective tissue growth factor (CTGF), which can act independently and sometimes oppositely to TGF-b and itself mediates many of the effects critical for diabetic nephropathy progression [33] . Bone morphogenic proteins (BMPs), particularly BMP-7, have been found to be protective growth factors that antagonize the effects of TGF-b and CTGF. Conversely, CTGF can bind to BMP-7 and antagonize its signaling, thereby promoting downstream effects consistent with worsening diabetic nephropathy [34] . Recently, a single group has published evidence suggesting a role for BMP-4 in aggravating, not ameliorating, diabetic nephropathy. The investigators studied a C57BL/6 mouse model of inducible BMP-4 overexpression which, though not specific for mesangial cells, promoted BMP-4 expression primarily in these cells in the kidney [35 && ]. Although the mice were not completely characterized in terms of systemic effects, they did develop glomerular changes consistent with early diabetic nephropathy including albuminuria, mesangial expansion, and glomerular basement membrane thickening [35 && ]. Conversely, modest changes of diabetic nephropathy found in STZ-diabetic C57BL/6 mice were attenuated in BMP-4 heterozygote knockout mice, though this latter finding is unconvincing given the limited nephropathy that develops in this mouse background. The same group then implicated BMP-4 in inducing chondrocyte markers as an aspect of its diabetic nephropathyinducing properties. One of these markers was SRYrelated HMG Box 9 (SOX-9) which itself induced chondrocyte changes in cultured mesangial cells [36 && ]. In type 1 diabetic BMP-4 transgenic mice, large amounts of SOX-9, collagen II, as well as diabetic nephropathy changes were documented.
Interestingly, although there were no changes in BMP-4 or BMP-7 gene expression in our Nephromine analysis of human diabetic nephropathy, there were substantial increases in SOX-9 in both glomeruli and tubulointerstitium of these diabetic nephropathy patients when compared with controls ( Fig. 3) .
Although preliminary, the data implicating BMP-4 and its effects on chondrocyte markers in diabetic glomeruli are intriguing and these reports should stimulate more interest in this signaling pathway as one potentially relevant to the progression of human diabetic nephropathy.
Dopamine signaling may ameliorate diabetic nephropathy
A relatively new concept in diabetic nephropathy research is that reduced dopamine handling and signaling by the proximal tubule may lead to worsening diabetic nephropathy through a number of mechanisms. L-DOPA is filtered and taken up by the proximal tubule epithelia and converted there into dopamine which in turn is largely metabolized by catechol-O-methyl transferase (COMT). A report this spring studied diabetic COMT knockout mice (on a nephropathic 129J/sv background) as a way to enhance proximal tubule dopamine levels and signaling [37] . The knockout diabetic mice showed a substantial amelioration of early hyperfiltration (probably via reduced cyclooxygenase 2 activity) as well as a reduction in albuminuria, mesangial expansion, and markers of renal fibrosis and oxidative stress in diabetic knockout mice with diabetes induced either by STZ or by crossbreeding with Akita mice compared to wildtype diabetic mice. Similar improvement was found in diabetic wildtype mice transplanted with a COMT knockout kidney, providing good evidence that it was the reduced COMT activity, and increased dopamine levels, in the kidney that specifically led to improved outcomes. Conversely, a model of selective proximal tubule intrarenal dopamine depletion was produced with a proximal tubule specific knockout of aromatic amino acid decarboxylase (AADC), the enzyme that converts L-DOPA to dopamine. These mice, made diabetic with STZ, developed a marked increase in albuminuria as well as increases in mesangial expansion, renal macrophage infiltration, and renal nitrotyrosine levels [37] . This reduction in dopamine signaling would result in a primary increase in proximal tubular salt and water reabsorption, in part via SGLT2, that could lead to hyperfiltration [38] as well as hypertension [39] .
On Nephromine analysis, COMT levels were significantly increased by 1.9-fold in the tubulointerstitium in diabetic nephropathy patients. There were no changes in COMT levels in the glomerulus or in AADC levels in either compartment. If all other processes were equivalent, the increased COMT levels could be associated with decreased tubulointerstitial dopamine levels.
Intrarenal dopamine may counteract some of the salt reabsorptive, hemodynamic, and profibrotic changes of progressive diabetic nephropathy. If these changes can be pathophysiologically confirmed in humans, it may open up another new target for intervention.
CONCLUSION
Small animal research in diabetic nephropathy, though hobbled by the lack of ideal models of progressive disease, has still been able to identify a number of new potential targets for intervention that can be investigated more fully in other models as well as in humans when appropriate. Targets identified in animal models require confirmation in humans. The increasing availability of annotated databases of human disease-specific expression data represents one approach to enable such confirmation. While adding to the complexity of the interconnected networks responsible for the disease process, recent research has opened up more possibilities where therapies may already exist or be available for clinical trials. A largely arbitrary (and alphabetical) list of those targets to be considered for targeting include dopamine (augment), eNOS (augment), JAK1/2 (inhibit), mTORC-1 (inhibit), and Nrf-2 (inhibit).
